Pharmaceuticals, Biotechnology and Life Sciences
Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement.
The FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction
Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS…
RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy for treating all stages of cancer, today announced a clinical collaboration with Merck.
Data Show KEYTRUDA Monotherapy Significantly Reduced the Risk of Disease Progression or Death by 35% Compared with BV
First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA Plus Concurrent Chemoradiation Achieved Objective Response Rate of 67.0%…
FDA has approves Merck’s Keytruda, pembrolizumab, for use at an additional recommended dose of 400 mg every six weeks for all approved adult indications.
Data showed the efficacy and safety of Keytruda 400 mg every six weeks (Q6W) comparable to approved 200 mg every three weeks (Q3W) regimen.
Noxxon Pharma said Friday that recruitment of patients in second cohort has been initiated for the middle dose cohort for the Phase 1/2 NOX-A12 plus radiotherapy brain cancer trial.
4D pharma Wednesday said that its clinical study with Merck to test MRx0518 combined with Keytruda further support its continued investment into our oncology franchise.